The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network
Valeria Cento(Rostov State Medical University), Francesca Ceccherini‐Silberstein(University of Cologne), Adriano Pellicelli(Carlo Forlanini Hospital), Giuliano Rizzardini, Laura Ambra Nicolini(Ospedale Policlinico San Martino), Bianca Bruzzone(Ospedale Policlinico San Martino), Vincenza Calvaruso(University of Palermo), Stefania Paolucci(Policlinico San Matteo Fondazione), M. Melis(University of Sassari), Chiara Dentone(Ospedale di Sanremo), Vincenzo Messina(Ospedale Sant'Anna), Simona Landonio(ASST Fatebenefratelli Sacco), M. Aragri(University of Rome Tor Vergata), Chiara Baiguera(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Sergio Babudieri(University of Sassari), Ada Bertoli(IRCCS Policlinico San Donato), Ilaria Lenci, Ennio Polilli(Azienda USL di Pescara), Giorgio Barbarini(Humanitas University), M. Angélico, Chiara Masetti(NHS Blood and Transplant), Nicola Coppola(University of Campania "Luigi Vanvitelli"), Velia Chiara Di Maio(University of Rome Tor Vergata), Alessia Ciancio(Department of Medical Sciences), Laura Sticchi(Ospedale Policlinico San Martino), T. Ruggiero, Giustino Parruti(Azienda USL di Pescara), Valeria Micheli(ASST Fatebenefratelli Sacco), Lucio Boglione(Ospedale Amedeo di Savoia), Raffaele Cozzolongo, Carmine Minichini(University of Campania "Luigi Vanvitelli"), Monica Schiavini(ASST Fatebenefratelli Sacco), Stefano Marenco(National Institutes of Health), Silvia Barbaliscia(University of Rome Tor Vergata), Ye. A. Troshina, Carlo Federico Perno(Centre International De Reference Chantal Biya), Antonio Craxı̀(University of Palermo), Marco Biolato(Agostino Gemelli University Polyclinic), C. Magni(ASST Fatebenefratelli Sacco), Filomena Morisco, Massimo Siciliano(Università Cattolica del Sacro Cuore), Massimo Puoti(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda)
Cited by 0
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
|The Lancet. Gastroenterology & hepatology|2022|664